CG Oncology Q2 net loss $41.4M; jury kills ANI royalties; BOND-003 75.5% CR

CG Oncology, Inc.

2025-Q2 EPS reported -$1.00 revenue$52,000

Net loss $41.4M ($0.54/sh) vs $18.9M ($0.28/sh) year ago; R&D $31.3M, G&A $17.4M.
Cash $661.1M; runway into 1H'28; BLA submission for cretostimogene planned in Q4'25.
Jury unanimously ruled CG owes no future royalties to ANI, eliminating 5% commercial royalty.
BOND-003 Cohort C: 75.5% CR at any time; 12-mo CR 50.7%, 24-mo CR 42.3% (K-M); median DOR 28 mo.
CORE-008 Cohort CX (cretostimogene + gemcitabine) initiated in HR BCG-exposed NMIBC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.